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Abstract: 9 
The extent of human intestinal absorption (HIA) for a drug is considered to be an important 10 
pharmacokinetic parameter which must be determined for orally administered drugs. 11 
Traditional experimental methods relied upon animal testing and are renowned for being time 12 
consuming, expensive as well as being ethically unfavourable. As a result, developing 13 
alternative methods to evaluate a drug’s pharmacokinetics is crucial. Micellar liquid 14 
chromatography (MLC) is considered to be one of these methods that can replace the use of 15 
animals in prediction of HIA. In this study, the combination of an aminopropyl column with 16 
the biosurfactant sodium deoxycholate (NaDC) bile salt were used in the experimental 17 
determination of micelle-water partition coefficients (log Pmw) for a group of compounds. 18 
Multiple linear regression (MLR) was then used for the prediction of HIA using the 19 
experimentally determined log Pmw along with other molecular descriptors leading to the 20 
construction of a model equation of R2= 85 % and a prediction power represented by R2Pred. 21 
=72 %. The use of MLC with an aminopropyl column in combination with NaDC was found 22 
to be a good method for the prediction of human intestinal absorption, providing data for a far 23 
wider range of compounds compared with previous studies. 24 
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1.Introduction: 34 
The use of micelles in HPLC was first introduced by Armstrong and Henry in 1980 (Berthod 35 
and Garcia-Alvarez-Coque 2000), now more commonly known as micellar liquid 36 
chromatography (MLC), and was used to enhance retention and selectivity of various solutes 37 
that would otherwise be inseparable or poorly resolved. MLC is an interesting technique for 38 
green chemistry as it uses a mobile phase containing 90 % or more water, these micellar mobile 39 
phases have low toxicity, are non-flammable and do not produce hazardous waste (Kanakaiah 40 
2013). Micellar liquid chromatography uses mobile phases containing a surfactant (ionic or 41 
non-ionic) above its critical micellar concentration (CMC) along with columns such as C18 42 
(and to a lesser extent cyanopropyl (CN)) (Kalyankar, Kulkarni et al. 2014; Rambla-Alegre 43 
2012). In MLC, surfactant monomers incorporated in the mobile phase adsorb on the porous 44 
RPLC packing altering the various surface properties of the stationary phase, such as surface 45 
area, polarity, structure, and pore volume which majorly influences chromatographic retention. 46 
The stationary phase pores are also coated by the surfactant molecules, decreasing their volume 47 
(Kalyankar, Kulkarni et al. 2014). Different stationary phases have different chemical 48 
characteristics which influence the elution of different groups of compounds where the 49 
formation of an aqueous layer over the stationary phase depends on the nature and the number 50 
of the chemically bonded groups therefore, determining the solutes’ partitioning. As a result, 51 
the use of a aminopropyl column was attempted in this work to help enhance the applicability 52 
of chromatography for absorption prediction where higher reactivity and polar interactions are 53 
important characteristics of amino columns as discussed in literature (Rambla-Alegre, Carda-54 
Broch et al. 2009; Gama, da Costa Silva et al. 2012).  55 
MLC has been applied to a variety of applications including prediction of transdermal 56 
permeation (Waters, Shahzad et al. 2013) through to oral drug absorption (Escuder-Gilabert, 57 
Martınez-Pla et al. 2003), blood brain barrier penetration (Escuder-Gilabert, Molero-Monfort 58 
et al. 2004) and ocular tissue permeability (Martın-Biosca, Molero-Monfort et al. 2003). In 59 
recent years, studies have also attempted to link chromatographically derived retention 60 
constants with pharmacokinetic predictors determined in silico and although linear 61 
relationships have been found (Milošević, Stojanović, Penov-Gaši, Perišić-Janjić, Kaliszan 62 
2014), these previously published studies depend upon the reliability of calculated data whereas 63 
this work attempts to correlate chromatographic data with published experimental data.  Solutes 64 
injected within an MLC system are classified according to their elution behaviour into three 65 
categories; binding, antibinding and non-binding. Binding solutes are those which bind or 66 
associate to micelles, they show decreased retention when the micelle concentration is 67 
increased. Antibinding solutes display increased retention with an increased concentration of 68 
micelles. Finally, non-binding solutes do not bind or associate to micelles displaying unaltered 69 
retention with changing micellar concentration. 70 
Previous work by the authors of this study presented the application of a cyanopropyl column 71 
as a stationary phase in an MLC system using a mixture of bile salts to determine human 72 
intestinal absorption (HIA) (Waters, Shokry et al. 2016; Shokry, Waters et al. 2018). However, 73 
for this study, an aminopropyl column was investigated as the stationary phase to determine 74 
the suitability of this alternative column for facilitating prediction of HIA.  75 
In summary, the work presented in this paper utilises micellar liquid chromatography to predict 76 
human intestinal absorption with sodium deoxycholate as the mobile phase and an aminopropyl 77 
column as the stationary phase. Previous studies have successfully utilised a system similar to 78 
this yet have been restricted by the variety of compounds that can be analysed based upon 79 
limitations as a consequence of the stationary phase employed. Through incorporating an 80 
aminopropyl column in to the system it is envisaged that a far wider range of compounds will 81 
be suitable for analysis thus expanding the potential applicability of the technique. 82 
2. Materials and Methods 83 
2.1 Materials 84 
Sodium deoxycholate (NaDC) was used as purchased from Sigma Aldrich, Dorset, UK (97 %). 85 
Analysed compounds using MLC were acetaminophen (99 %, Sigma Aldrich, Dorset, UK), 86 
acetyl salicylic acid (99 %, Acros organics, Geel, Belgium), caffeine (97 %, Sigma Aldrich, 87 
Dorset, UK), carbamazepine (99 %, Sigma Aldrich, Dorset, UK), cimetidine (Sigma Aldrich, 88 
Dorset, UK), diclofenac (98 %, TCI, Zwijndrecht, Europe), fenoprofen (97 %, Fluka, Dorset, 89 
UK), fluconazole (98 %, Sigma Aldrich, Dorset, UK), flurbiprofen (98 %, TCI, Zwijndrecht, 90 
Europe), gemfibrozil (98 %, TCI, Zwijndrecht, Europe), ibuprofen (98 %, BASF, Cheshire, 91 
UK), indomethacin (99 %, Sigma Aldrich, Dorset, UK), ketoprofen (98 %, Sigma Aldrich, 92 
Dorset, UK), lidocaine (98 %, Sigma Aldrich, Dorset, UK), lornoxicam (>98 %, TCI,  93 
Zwijndrecht, Europe), meloxicam (98 %, TCI, Zwijndrecht, Europe), naproxen (98 %, Sigma 94 
Aldrich, Dorset, UK), nicotinic acid (99.5 %, Sigma Aldrich, Dorset, UK), phenylbutazone 95 
(98.5 %, Sigma Aldrich, Dorset, UK), piroxicam (98 %, Sigma Aldrich, Dorset, UK), salicylic 96 
acid (99 %, Fisher Scientific, Loughborough, UK),  theophylline (98 %, TCI, Oxford, UK) and 97 
terbutaline (96 %, Sigma Aldrich, Dorset, UK) used as purchased. Deionised water was 98 
prepared using a Barnstead™ Ultrapure system. 99 
2.1 Preparation of NaDC solutions used as mobile phase: 100 
A 20 mM stock solution of NaDC bile salt in water was prepared by transferring an accurately 101 
weighed amount of NaDC to a 250 mL volumetric flask and completing to the mark with 102 
deionised water. Accurately measured aliquots were then transferred from the stock solution to 103 
50 mL volumetric flasks; solutions were then completed to the final volume with deionised 104 
water to give NaDC solutions of concentrations within the range of (5-20 mM). 105 
2.2 Experimental Procedure 106 
Micellar liquid chromatography required injection of 20 μL samples of twenty-three 107 
compounds (0.2 mM) into a Rheodyne injector and pumped with the mobile phase through a 108 
reversed phase aminopropyl column (APS) (Hypersil 5µm, 15 cm x 4.6mm, Thermo Fisher 109 
Scientific, MA, USA) using an Agilent1100 Series Binary pump at a flow rate of 1.34 mL/min. 110 
The retention of the solutes within the column was detected using a UV detector (Perseptive 111 
Biosystems UVIS-205, MA, USA), set at a wavelength appropriate for each drug and recorded 112 
via Picolog software indicating retention times. The mobile phase was filtered through a 0.45 113 
µm Nylon filter and degassed in an ultrasonic bath. The recorded data were analysed to obtain 114 
retention factors and each sample was repeated in triplicate to ensure that reasonable accuracy 115 
and precision were achieved using a series of mobile phases of NaDC concentrations. A 116 
minimum of five concentrations were analysed per drug ranging from 5-20 mM. All 117 
experiments were performed at room temperature. 118 
2.3 Determination of Dead time (t0) 119 
The dead time (t0) (time taken by the solvent front to reach the detector) was measured by the 120 
injection of water in to the system (Pramauro, Minero et al. 1988)  for the appearance of the 121 
first major perturbation to the baseline. The dead time was calculated from an average of ten 122 
results. 123 
2.4 Calculation of Log Pmw  124 
From the recorded retention times for each compound and the dead time, retention factors (k) 125 
were calculated as follows: 126 
k =
(Retention time−dead time) 
dead time
           Eq. (1) 127 
The CMC value of NaDC was taken to be 5 mM (Olesen, Westh et al. 2015) and the micellar 128 
concentration (CM) was then calculated for each NaDC concentration used as follows: 129 
(CM) = Total surfactant concentration − Critical micellar concentration (CMC)   Eq. (2) 130 
On the basis of a linear relationship between micellar concentration (CM) and (1/k) according 131 
to the equations described by Arunyanart and Love (1985), the log of the partition coefficient 132 
(log Pmw) can be determined for each compound by: 133 
Log Pmw = log [intercept slope⁄ ]             Eq. (3)  134 
3. Results: 135 
Prior to this study, the use of NaDC as a mobile phase (with an alternative column) confirmed 136 
the potential of MLC in the prediction of HIA (Waters, Shokry et al. 2016).  A further study 137 
considered the effect of changing the mobile phase composition confirming the use of a mixture 138 
of NaDC along with phospholipid was a better predictive system of HIA than NaDC alone 139 
(Shokry, Waters et al. 2018). This current study explores the effect of an alternative stationary 140 
phase regarding HIA predictive capability. 141 
3.1 Selection of Aminopropyl column 142 
According to literature, aminopropyl columns are widely used especially in hydrophilic 143 
interaction liquid chromatography (HILIC). They also offer a more reactive, selective and 144 
efficient stationary phase and polar interactions are more abundant than in cyanopropyl 145 
columns (Rambla-Alegre, Carda-Broch et al. 2009; Gama, da Costa Silva et al. 2012). Also 146 
aminopropyl columns offer the possibility of anion exchange mechanisms around neutral pH 147 
(Olsen 2001). Compounds such as amines, ethers, esters and ketones are preferentially retained 148 
on amino columns compared with cyano columns. This could be the reason why more 149 
compounds were analysed using this column (rather than a cyano column) in the previous 150 
study. Furthermore, because of general concerns about stability and reproducibility, 151 
cyanopropyl columns are less commonly used overall.  152 
3.2 Effect on retention behaviour 153 
Experimental data for the calculated log Pmw values, along with published physicochemical 154 
data utilised for analysis are presented within ‘Supplementary Information’ (Table S1). The 155 
use of an aminopropyl column as a stationary phase had a great impact on the retention profiles 156 
for a number of the analysed compounds (including neutral, anionic and cationic compounds) 157 
using MLC. Therefore, there was an appreciable effect on the obtained log Pmw values which 158 
is a reflection of the partitioning process of the compounds under study. The dead time average 159 
value was determined to be 79.40 seconds. 160 
Ideally, neutral and cationic drugs are expected to show binding behaviour whilst anionic drugs 161 
are expected to show antibinding behaviour with the increase in the bile salt concentration. 162 
Interestingly, the opposite to what was expected was observed in that neutral compounds 163 
displayed antibinding behaviour whilst cationic and anionic drugs displayed both binding and 164 
antibinding behaviour according to their molecular weight.  165 
3.2.1 Theory behind retention behaviour 166 
Salt bridge formation is assumed to be the justification behind the change in the way drugs 167 
interacted with the stationary phase (aminopropyl column) that led to unconventional patterns 168 
of elution. This assumption is supported by the work of Takeuchi et al. who presented the 169 
possibility of using bile acids as stationary phases in liquid chromatography through their 170 
immobilisation on aminopropyl silica through electrostatic interactions (Takeuchi, Chu et al. 171 
1998). A salt bridge is a combination of two noncovalent interactions which are hydrogen 172 
bonding and electrostatic interactions. Although such bridges are abundant in protein folded 173 
conformations (to provide stability) they are also found in supramolecular chemistry. Since the 174 
pH of the medium was found to be in the range of (6.4-8.0) the amino group (-NH2) is thought 175 
to undergo protonation converting to the ammonium ion (-NH3
+) and, in this case, rendering 176 
the column positively charged. As a result, a salt bridge is assumed to have formed through 177 
electrostatic attraction between the negatively charged carboxylic group (–COO-) of NaDC and 178 
the positively charged ammonium group (-NH3
+) of the column also, through hydrogen 179 
bonding between the hydrogen atom of the ammonium group (-NH3
+) and the oxygen atom of 180 
the carboxylic group (–COO-) which adds up to the overall stability of the formed network as 181 
it acts as a small stabilising interaction (Anslyn and Dougherty 2006). The charge on both the 182 
column and the bile salt adsorbed on its surface are masked by their electrostatic attraction. 183 
Salt bridges form between the bile salt monomers and the column creating a stable network. 184 
Also, hydrogen bonds form between the bile salts hydroxyl groups as well as the nonpolar 185 
binding of the hydrophobic moiety of NaDC molecules, creating a network with free monomers 186 
from the mobile phase leading to the formation of the appearance of bilayers of bile salt. 187 
Although some anionic drugs displayed antibinding behaviour (which is typical for 188 
conventional retention), a number of anionic drugs exhibited the opposite behaviour i.e. a 189 
binding interaction with NaDC. Both cases can be explained according to the previously 190 
mentioned theory for bile salt (micellar mobile phase) interactions with the aminopropyl 191 
column used in this method. 192 
The anionic drugs (fenoprofen, ibuprofen, gemfibrozil and phenylbutazone) displayed a 193 
retention behaviour typical for that expected for anionic compounds with anionic surfactant 194 
with an antibinding interaction with the NaDC micelles. On the other hand, three anionic drugs, 195 
namely lornoxicam, meloxicam and piroxicam displayed an opposite pattern of interaction as 196 
they acted as binding solutes. This is unusual for anionic drugs when analysed with anionic 197 
surfactants in MLC.  198 
The typical antibinding behaviour of anionic compounds can be attributed to the electrostatic 199 
repulsion taking place between the negatively charged compounds and the negatively charged 200 
surfactant. As a result of this repulsion the compound bound to the column displayed an 201 
increase in retention on the column with the increase in the surfactant concentration. In this 202 
case the drug must have a low molecular weight in order to be entrapped inside the layers of 203 
the bile salt network structure formed with the aminopropyl column by means of electrostatic 204 
attraction and hydrogen bonding. As a result, fenoprofen, ibuprofen, gemfibrozil and 205 
phenylbutazone, having relatively low molecular weights of 242.3, 206.3, 250.3 and 308.4 206 
g/mol respectively (http://www.chemspider.com/), were entrapped inside the bile salt network 207 
structure displaying an antibinding interaction. However, lornoxicam, meloxicam and 208 
piroxicam, having relatively higher molecular weight values of 371.8, 351.4 and 331.4 g/mol 209 
respectively (http://www.chemspider.com/), could not be entrapped inside the bile salt network 210 
structure. Instead, they were entrapped inside the micellar core, overcoming the repulsion 211 
forces with the micelles as a consequence of their high molecular weights (Figure 1). 212 
For neutral drugs (acetaminophen, caffeine, fluconazole and theophylline), an antibinding 213 
retention behaviour was observed which is again, against convention, where neutral drugs 214 
traditionally undergo a binding interaction. This can be attributed to the preference of these 215 
drugs to bind to the more stable hydrophobic core of the bile salt network structure rather than 216 
that of the bile salt micelles in the mobile phase. Also these drugs have comparatively low 217 
molecular weights of 151.2, 194.2, 306.27, 180.2 g/mol respectively 218 
(http://www.chemspider.com/), facilitating entrapment within the hydrophobic core of the bile 219 
salt network structure within the column therefore showing antibinding retention behaviour. 220 
 221 
Figure 1: Chromatograms displaying the binding behaviour of meloxicam over a series of 222 
mobile phase concentrations with an aminopropyl column as a stationary phase. (The dotted 223 
line is only used for visual guidance). 224 
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3.3 Prediction of human intestinal absorption (HIA) 225 
Statistical data analysis was conducted using Minitab 17® software. Multiple linear regression 226 
was carried out where different molecular descriptors collected from literature were regressed 227 
against the dependant variable %HIA and a backward elimination modelling strategy was 228 
carried out. To take variance inflation factors (VIF) to acceptable limits, variables with high 229 
(VIF) were removed. Finally, an optimum model was obtained that provides a good summary 230 
of data, this was undertaken in a similar manner to that previously published (Waters, Shokry 231 
et al. 2016).    232 
The variables remaining in the optimal model were assessed for significance and relative 233 
importance by standardised coefficients and the associated p-values. 234 
The predictive ability of the final model was assessed using adjusted-R2 and R2 for prediction 235 
(R2PRED) derived from predicted residual error sum of squares (PRESS statistic). The predictive 236 
ability of the model was indicated by R2PRED which consequently reflects the model’s 237 
applicability. 238 
In this study, a group of twenty-three drugs were analysed using the MLC system using an 239 
aminopropyl (APS) column and log Pmw was calculated for each compound, a number of 240 
molecular descriptors such as molecular weight (Mwt), polar surface area (PSA), freely 241 
rotating bonds (FRB), molar volume (VM), dissociation constant (pKa), aqueous solubility (Sw), 242 
number of hydrogen bond donors (nHD) and number of hydrogen bond acceptors (nHA) were 243 
used along with the obtained log Pmw to develop a mathematical model for prediction of %HIA. 244 
Logit (%HIA) was used to improve the linear relationship between published (%HIA) and 245 
experimental log Pmw values as seen in studies of a similar type (Norinder, Österberg et al. 246 
1999; Raevsky, Fetisov et al. 2000; Zhao, Abraham et al. 2002). The human intestinal 247 
absorption values were transformed to logit by substitution in Equation 4. 248 
Logit (%HIA) = log (%HIA / (100-%HIA))                Eq. (4) 249 
For simplification, all drugs of 100 or 0 % HIA were excluded from the training set. 250 
Log Pmw was successfully included with 2 other molecular descriptors in the final model 251 
equation with %HIA experimental values for orally administered drugs which successfully 252 
predicted the %HIA with 72 % predictability. The final model was validated using a set of 253 
seven compounds. 254 
The model obtained for the prediction of %HIA is given by Equation 5: 255 
 256 
logit %HIA = -0.758 – 0.369 log Pmw + 0.01157 VM + 0.0714 Sw         Eq. (5) 257 
Sixteen drugs were used in the development of the final model. The model’s R2 = 84.62 %,  258 
R2adjust.= 80.77 % , R
2
PRED = 71.51 %, S= 0.203 259 
A 95 % confidence interval for log Pmw is given by (-0.726, -0.011), t-statistic and standardised 260 
coefficient of log Pmw are –2.25 (p<0.05) and -0.294 respectively suggesting statistical 261 
significance of log Pmw as a predictor. Also the F-ratio of the overall model is statistically 262 
significant, F= 22 and P value 0.000 (p<0.05). Figure 2 shows no marked relationship between 263 
residuals and predicted values while Figure 3 summarises the model. 264 
Seven drugs (cimetidine, fenoprofen, lornoxicam, nicotinic acid, piroxicam, salicylic acid and 265 
terbutaline) were used to test the model predictability. The model was able to predict the %HIA 266 
for these drugs within a minimum of 0.1 % and a maximum of 8 % difference between the 267 
predicted %HIA and the published %HIA. The model appears to have underestimated %HIA 268 
for both lornoxicam and salicylic acid with a 12 % and 24 % difference between the two 269 
predicted and published values. The relationship between the predicted and the experimental 270 
%HIA values is shown in Table 1 and Figure 4. 271 
Comparing this current model with that obtained with the MLC system using a cyanopropyl 272 
column; logit HIA = -0.410 - 0.482 log Pmw + 0.00852 Mwt + 0.04799 Sw (Waters, Shokry et 273 
al. 2016), it is observed that three predictors were included in each model: (log Pmw and Sw) in 274 
both models, Mwt (in CN column derived model) and VM (in APS column derived model). 275 
According to literature, molecular weight (Mwt) and molar volume (VM) are both estimates of 276 
size however, VM takes into consideration both the size and shape as it is very much related to 277 
molecular surface area which offers a better guide to estimate the potential for permeability 278 
(Smith, Walker et al. 2006). Although both models have nearly the same HIA prediction ability, 279 
this current model was obtained based on a larger data set where the change of the used column 280 
from CN to APS allowed the analysis of a larger number of compounds. This is because the 281 
latter column resulted in compound-stationary phase interactions that facilitated calculation of 282 
values for compounds that had been unsuccessfully analysed using the former column type.  283 
Finally, combining the results of changing the column type from CN to APS and changing the 284 
type of micellar mobile phase from NaDC to a physiological mixture of bile salts with lecithin, 285 
it is hypothesised that the use of an MLC system that combines the use of an APS column with 286 
bile salts with lecithin as a mobile phase would provide a more reliable HIA predictive model 287 
covering a wider range of %HIA prediction. 288 
 289 
 290 
 291 
Figure 2: Residual plot for optimal logit HIA regression model. 292 
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 314 
Figure 3: Partial regression plots of experimental logit HIA. values against log Pmw, VM and 315 
Sw . 316 
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Table 1: Experimental and predicted values for %HIA. 320 
Drug Expt. %HIA Pred. %HIA Reference 
Acetaminophen 95.00 94.82 (±0.04) 
(Castillo-Garit, Cañizares-
Carmenate et al. 2014) 
Acetylsalicylic 
acid 
82.00 87.00 (±0.04) 
(Castillo-Garit, Cañizares-
Carmenate et al. 2014) 
Caffeine 99.00 98.42 (±0.01) (Yan, Wang et al. 2008) 
Carbamazepine 70.00 73.53 (±0.09) 
(Varma, Sateesh et al. 
2005) 
Cimetidine* 73.50 73.60 (±0.05) 
(Veber, Johnson et al. 
2002; Yan, Wang et al. 
2008) 
Diclofenac 90.00 90.73 (±0.01) 
(Molero-Monfort, 
Escuder-Gilabert et al. 
2001) 
Fenoprofen* 85.00 93.07 (±0.06) (Hou, Wang et al. 2007) 
Fluconazole 97.50 98.29 (±0.05) 
(Castillo-Garit, Cañizares-
Carmenate et al. 2014) 
Flurbiprofen 92.00 84.68 (±0.01) (Raevsky 2004) 
Gemfibrozil 95.00 96.57 (±0.05) 
(Paixão, Gouveia et al. 
2012) 
Ibuprofen 85.00 90.25 (±0.01) 
(Paixão, Gouveia et al. 
2012) 
Indomethacin 99.00 98.22 (±0.04) (Chu 2009) 
Ketoprofen 96.00 92.94 (±0.05) 
(Castillo-Garit, Cañizares-
Carmenate et al. 2014) 
Lidocaine 95.00 96.30 (±0.02) 
(Molero-Monfort, 
Escuder-Gilabert et al. 
2001; Chu 2009) 
Lornoxicam* 100.00 88.67 (±0.06) 
(Newby, Freitas et al. 
2015) 
Meloxicam 90.00 92.40 (±0.06) 
(Castillo-Garit, Cañizares-
Carmenate et al. 2014) 
Naproxen 94.00 91.02 (±0.05) 
(Castillo-Garit, Cañizares-
Carmenate et al. 2014) 
Nicotinic acid* 94.00 100.00 (±0.01) (Yan, Wang et al. 2008) 
Phenylbutazone 98.00 98.36 (±0.01) (Hou, Wang et al. 2007) 
Piroxicam* 99.00 92.28 (±0.05) (Chu 2009) 
Salicylic acid* 99.00 75.44 (±0.08) (Raevsky 2004) 
Theophylline 98.00 98.24 (±0.01) 
(Kansy, Senner et al. 
1998) 
Terbutaline* 80.00 84.25 (±0.01) (Grès, Julian et al. 1998) 
The asterisk (*) indicates the validation compounds. 321 
 322 
 323 
Figure 4: Plot of experimental vs. predicted  %HIA. 324 
 325 
4. Conclusion: 326 
The change in the type of the stationary phase used in the MLC method from cyanopropyl to 327 
aminopropyl (APS) had a significant impact on the interaction of the analysed drugs with both 328 
the micellar mobile phase and the stationary phase used and consequently on their elution. This 329 
method was able to predict %HIA using a reliable model. This MLC method has one major 330 
advantage over that previously published with a different column in that it permits analysis of 331 
a greater number of compounds than that analysed prior to this study. This is because some 332 
compounds displayed non-binding behaviour in the previously published method (i.e. it was 333 
not possible to calculate log Pmw for these compounds) yet they displayed binding or 334 
antibinding behaviour using this method. This expanded study helps in the establishment of a 335 
reliable model for prediction of HIA from a wider dataset.  It is hypothesised that by combining 336 
the physiologically relevant mixture of bile salts that displayed good HIA predictability with 337 
the column used in this study (R2pred.=81%) could create a mathematical model with an even 338 
higher predictive ability that could be developed based on a greater number of compounds in 339 
both the training and validation sets. 340 
 341 
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